Immunopathology of acetylcholine receptors in myasthenia gravis.
It is now clear that the muscular weakness and fatigability seen in MG result from an antibody-mediated immune response to AChR. The mechanisms by which antibodies impair transmission are moderately well understood and detection of antibodies in patient's sera is a reliable diagnostic test for the disease. The spectrum of antibody specificities produced in MG is also beginning to be understood, largely through the use of antibodies produced in the experimental model EAMG. Treatment for MG continues to rely heavily on the symptomatic relief afforded by acetylcholinesterase inhibitors. However, the recent recognition of the autoimmune nature of MG has led to increased emphasis on immunosuppression and antibody removal with some beneficial effects. Despite all that has been learned, the level of ignorance has just been pushed back one step--from the neuromuscular junction to the immune system. What initiates the immune response to AChR in MG and how to specifically suppress this aberrant response remain completely unknown.
D000110:Acetylcholinesterase; D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000906:Antibodies; D001327:Autoimmune Diseases / Q000276:immunology; D002800:Cholinesterase Inhibitors / Q000627:therapeutic use; D006801:Humans; D007130:Immunoglobulin Idiotypes / Q000276:immunology; D007165:Immunosuppression Therapy; D009157:Myasthenia Gravis / Q000276:immunology* / Q000628:therapy; D009469:Neuromuscular Junction / Q000276:immunology; D010956:Plasmapheresis; D011950:Receptors, Cholinergic / Q000276:immunology*; D013950:Thymus Gland / Q000601:surgery
D000305:Adrenal Cortex Hormones; D000906:Antibodies; D002800:Cholinesterase Inhibitors; D007130:Immunoglobulin Idiotypes; D011950:Receptors, Cholinergic; D000110:Acetylcholinesterase